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Background: Cyclin E is a cell cycle regulator which is critical for driving G1/S transition. Abnormal levels of cyclin E
have been found in many cancers. However, the level changes of cyclin E in esophageal adenocarcinoma and its
precancerous lesion have not been well studied. Here, we focus on the gene amplification and expression of cyclin
E in these lesions, and aim to ascertain the relationship with clinicopathological characteristics.
Methods: Genomic DNA was analyzed from 116 esophageal adenocarcinoma and 26 precancerous lesion patients
using Affymetrix SNP 6.0 arrays. The protein overexpression of cyclin E was also detected using
immunohistochemistry from tissue microarrays containing esophageal adenocarcinoma and precancerous lesions.
Patient survival and other clinical data were collected and analyzed. The intensity and percentage of the cyclin E
expressing cells in tissue microarrays were scored by two pathologists. Fisher exact tests and Kaplan-Meier methods
were used to analyze data.
Results: By genomic analysis, cyclin E was amplified in 19.0% of the EAC samples. By immunohistochemistry, high
expression of cyclin E was observed in 2.3% of squamous mucosa tissues, 3.7% in columnar cell metaplasia, 5.8% in
Barrett’s esophagus, 19.0% in low grade dysplasia, 35.7% in high grade dysplasia, and 16.7% in esophageal
adenocarcinoma. The differences in cyclin E high expression between neoplastic groups and non-dysplasia groups
are statistically significant (p < 0.05). The prognosis for patients with high cyclin E expression appeared slightly better
than for those with low cyclin E expression although this was not statistically significant (p = 0.13).
Conclusions: The expression of cyclin E significantly increases from non-dysplasia esophageal lesion to low and
high grade dysplasia, suggesting that cyclin E plays an important role in the early stage of carcinogenesis.
Importantly, cyclin E is also amplified and highly expressed in a subset of esophageal adenocarcinoma patients, but
this increase is not associated with worse prognosis.
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The incidence of esophageal adenocarcinoma (EAC) has
increased approximately 600% in the US and other
Western Countries over the last 30 years [1]. EAC tends
to be diagnosed late with most patients in locally advanced
or metastatic disease. Consequently, the overall prognosis
for patients with EAC is very poor at approximately 15%,
with 5-year overall survival. More than 50 percent of pa-
tients have either unresectable tumors or radiographically
visible metastases at the time of diagnosis [2]. Identifica-
tion of early biomarkers with high sensitivity and specifi-
city will provide physicians with valuable information for
surveillance, diagnosis, prognosis, and possible treatment
options for esophageal adenocarcinoma. Previous studies
have suggested that esophageal adenocarcinoma develops
in the following order: normal esophageal epithelium, re-
flux esophagitis, Barrett’s esophagus (BE), dysplasia, and fi-
nally esophageal adenocarcinoma [3]. During these events,
a series of genetic and epigenetic aberrations contributes
to the carcinogenesis, which will be potential biomarkers
for early screening, surveillance and treatment of the
dysplasia and adenocarcinoma.
Cyclin E, an activating subunit of cyclin dependent
kinase 2 (CDK2), is encoded by human cyclin E1 gene
(CCNE1) on chromosome 19q12-13. Cyclin E plays a
key role to promote G1 cell cycle transition to S-phase.
The oncogenic activity of cyclin E is involved in multiple
functions including a regulatory network comprised CDK
inhibitors, the p53 and FBW7 tumor suppressor pathways,
signal transduction pathways, controlling cell cycle pro-
gression, and microRNAs [4,5]. Genetic and pharmaco-
logic targeting of the cyclin E-CDK-2 complex resulted in
marked growth inhibition of lung cancer cells [6], suggest-
ing a potential chemotherapeutic approach for lung can-
cer. In breast cancer, the depletion of cyclin E by siRNA
promoted apoptosis of cyclin E overexpressing cells and
blocked their proliferation, transformation phenotype and
tumor growth in nude mice. Liang and colleagues con-
cluded that cyclin E may serve as a novel and effective
therapeutic target [7]. In addition, the amplification and
overexpression of cyclin E have been reported in a variety
of cancers including breast [7,8], lung [9], ovarian [10],
stomach [11,12], colorectal [13,14], bladder [15], endomet-
rial carcinoma [16] and thyroid [17]. In the esophagus, a
few studies found cyclin E amplification and overexpres-
sion in esophageal adenocarcinoma and precancerous
lesion in small samples [18-21].
The cyclin E expression was first reported in low-grade
dysplasia (2/21), high grade dysplasia (3/17), adenocarcin-
oma (5/35) and Barrett’s esophagus (43%) in 60 samples
by an immunohistochemistry [21,22]. Cyclin E gene ampli-
fication in esophageal adenocarcinoma was also confirmed
in 13.8% (9/65) [19] and 12.6% (11 of 87) [20] in esophageal
adenocarcinoma by quantitative PCR molecular analysis[19,20]. However, the sample size of previous studies is
small and the results were not consistent. In addition, the
relationship between high expression of cyclin E or gene
amplification and the patient survival is unknown.
In the current study, we (i) used high resolution SNP
DNA microarray to study cyclin E amplification in the
large scale of esophageal adenocarcinoma and precancer-
ous lesions; (ii) used immunohistochemical method to
confirm the high expression of cyclin E in a larger number
of esophageal adenocarcinoma and precancerous lesions;
and (iii) studied the association of cyclin E amplification
and high expression with patients’ overall survival and
clinicopathological features.
Methods
Patients for Affymetrix SNP 6.0 analysis
Frozen tumors were obtained from 116 patients undergo-
ing esophagectomy at the University of Pittsburgh Medical
Center, Pittsburgh, PA between 2002 and 2008. Patient
age ranged from 43–88 and the cohort consisted of 95
males and 21 females. Final pathologic stages were stage I
(28), stage II (31), stage III (50) and stage IV (7). All tumor
specimens were evaluated by a pathologist and were deter-
mined to be >70% tumor cell representation. Only 112
specimens were used for survival analysis as we excluded
4 peri-operative chemotherapy patients.
Frozen Barrett’s esophagus (intestinal metaplasia: n = 26)
and esophageal columnar cell metaplasia (metaplasia
without goblet cells; n = 25) biopsy tissues were obtained
from patients undergoing endoscopy at the University of
Rochester Medical Center from 2008 to 2012. All patho-
logic diagnoses were evaluated by pathologists. All studies
were approved by research subjects review board at Uni-
versity of Pittsburgh and University of Rochester.
Affymetrix SNP 6.0 analysis
Genomic DNA was isolated using the QiaAmp DNA
Mini Kit (Qiagen, CA) and 600 mg was used for labeling
and array hybridization at the SUNY Upstate Medical
University microarray core facility (Syracuse, NY) using
kits and protocols provided by Affymetrix. Data analysis
was performed using Nexus 6.0 Copy Number Analysis
software (Biodiscovery, Inc. CA). Log2 DNA copy num-
ber ratios for the tumor and pre-neoplastic samples were
generated in reference to a baseline file created using DNA
from normal esophageal mucosa from a subset (n = 15) of
the Pittsburgh patient cohort. Data was segmented using
the SNP-Rank segmentation algorithm with a minimum of
8 probe sets and significance threshold of p-value of 10−6.
Log2 copy number threshold for gains were set at +0.15
(~2.2 copies) while high level gains were set at +0.5 (~2.8
copies). More information on this patient cohort and a
comprehensive genomic analysis of these tumors is to be
published by Dulak et al [23]. Microarray data on this
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bus (GSE36460) with an online link (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE36460).
Construction of tissue microarray
Tissue microarrays, containing 34 cases of Barrett’s
esophagus (BE), 81 cases of columnar cell metaplasia
(CCM), 86 cases of squamous epithelium (SE), 21 cases
of low grade dysplasia (LGD), 14 cases of high grade
dysplasia (HGD), and 117 cases of esophageal adenocarcin-
oma (EAC), were constructed from the representative areas
of formalin-fixed specimens collected between 1997–2005
in the Department of Pathology and Laboratory Medicine,
University of Rochester Medical Center/Strong Memorial
Hospital, Rochester, New York. Five-micron sections were
cut from tissue microarrays and were stained with H&E to
confirm the presence of the expected tissue histology
within each tissue core. Additional sections were cut for
immunohistochemistry analysis.
Patients for tissue microarrays
All 117 patients with EAC used for the tissue microarray
construction were treated with esophagectomy at Strong
Memorial Hospital/University of Rochester from 1997 to
2005. These patients included 105 males and 12 females.
The patients’ ages ranged from 34 to 85 years (Table 1).
The follow-up period after esophagectomy ranged from
0.3 to 142 months with a mean of 39 months.
Immunohistochemistry
Tissue sections from the tissue microarray were deparaf-
finized, rehydrated through graded alcohol, and washed
with phosphate buffered saline. Antigen retrieval for cyc-
lin E was performed by heating sections in 99°C water
bath for 40 minutes. After endogenous peroxidase activ-
ity was quenched and nonspecific binding was blocked,
ready-to-use mouse monoclonal antibody anti-cyclin E
(Santa Cruz, CA) was incubated at room temperature
for 30 minutes. The secondary antibody (Flex HRP) was
allowed to incubate for 30 minutes. After washing, sec-
tions were incubated with Flex DAB Chromogen for
10 minutes and counterstained with Flex HematoxylinTable 1 Distribution of patients in Age and Sex with
esophageal adenocarcinoma and precancerous lesion
using immunohistochemical study
Diagnosis Total Female Male Age
Adenocarcinoma 117 12 105 65
High grade dysplasia 14 2 12 67
Low grade dysplasia 21 0 21 71
Barrett’s esophagus 34 4 30 67
Columnar cell metaplasia 81 7 74 64
squamous epithelium 86 19 67 65for 5 minutes. A colon adenocarcinoma with known cyc-
lin E high expression served as positive control. Negative
control was performed by replacing the anti-cyclin E
antibody with the normal serum. Several tissue cores
were falloff glass during this processing.Scoring of immunohistochemistry
All sections were reviewed independently by JY and ZZ
blinded to all clinical and pathologic information. Dis-
cordant cases were reviewed by both JY and ZZ and a
final consensus was reached. The percentage (0-100%) of
the cells with positive nuclear staining was recorded.
The intensity of cyclin E nuclear staining was graded as
0, 1+, 2+, or 3+. No nuclear stain or positive nuclear stain
in less than 10% was defined as 0 (Figure 1A); weakly
nuclear stain in 10% or more cells was defined as 1+
(Figure 1B); relatively strong nuclear stain in 10% or
more cells was defined as 2+ (Figure 1C); very strong
nuclear stain in 10% or more cells was defined as 3+
(Figure 1D). Cyclin E protein was considered highly
expressed if 10% or more of cells stained with a moderate
to strong intensity (2+ and 3+, respectively) (Figure 1).Statistical analysis
All the descriptive statistics in this study were presented
as means. A P-value of less than 0.05 was considered
statistically significant. The univariate analysis with cyc-
lin E was conducted first and then followed with a
multivariate analysis, including age, gender, and clinical
covariates: lymph node metastasis and tumor stage.
Chi-square and Fisher exact tests were used as appro-
priately to compare cyclin E positivity rates from col-
umnar cell mucosa, dysplasia to adenocarcinoma. To
evaluate the influence of high expression of cyclin E in
esophageal adenocarcinoma, comparative risk analysis
using the Kaplan-Meier method cooperated with the
log-rank test was performed with cyclin E amplified and
non-amplified groups. All the statistical analyses were
conducted with SAS 9.3 software (SAS Institute Inc.,
Cary, NC).Results
Genomic analysis of cyclin E amplification
Analysis of 116 EAC specimens using high density copy
number microarrays revealed amplification of CCNE1 in
19.0% (22/116) (Figure 2). In this cohort, the median
overall survival of patients with CCNE1 amplification
was approximately 20 months compared with 25 months
for those without amplification (p = 0.22). CCNE1 ampli-
fication was not observed in Barrett’s esophagus (0/26)
or columnar cell metaplasia specimens (0/25).
Figure 1 The intensity of cyclin E immunohistochemical study with nuclear staining. A. 0; Negative or very week intensity of cyclin E
nuclear stain in one EAC sample; B. 1+: weak intensity of cyclin E nuclear stain in one EAC sample; C. 2+: moderate intensity of cyclin E nuclear
stain in one EAC sample; and D. 3+: strong intensity of cyclin E nuclear stain in one EAC sample.
Figure 2 Frequency histogram showing amplification of the CCNE1 locus at chromosome 19q12-13 in 116 esophageal adenocarcinoma
samples using high density copy number SNP microarrays. This locus is amplified in 22/116 (19.0%) cases in this patient cohort, approximately half
of which are considered high copy number amplification events.
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cyclin E expression
By immunohistochemical analysis, high expression of
cyclin E was observed in 2.3% of normal squamous mu-
cosa (2/86), 3.7% in columnar cell metaplasia (3/81), 5.8%
in Barrett’s esophagus (2/34), 19.0% in low grade dysplasia
(4/21), and 35.7% in high grade dysplasia (5/14). In
esophageal adenocarcinoma high cyclin E expression was
observed in 16.7% (19/114) of cases. This was not statisti-
cally significantly different from high grade dysplasia.
Qualitatively, we observed that normal squamous mucosa
and columnar cell metaplasia usually have weak, focal
staining whereas high grade dysplasia or adenocarcinoma
have strong, diffuse staining (Table 2 and Figure 3).
Chi-square and Fisher exact tests were used to com-
pare cyclin E percentages among all various histological
groups including squamous epithelium, columnar cell
mucosa, Barrett’s esophagus, low- and high-grade dys-
plasia, and adenocarcinoma. The differences of cyclin E
high expression between all neoplastic groups (including
EAC, HGD and LGD) and non-dysplasia groups (includ-
ing CCM and SE) are statistically significant (p < 0.05)
(Table 3). No significant difference is identified among
neoplastic groups. In addition, no significant difference
of cyclin E high expression is identified between squamous
mucosa and columnar cell metaplasia. Barrett’s esophagus
group is only significantly different from high grade dys-
plasia (Table 3).
Survival analysis of cyclin E high expression in EAC
Kaplan-Meier analysis and the log-rank test were used
to calculate the effect of the cyclin E high expression in
patients with EAC on survival. The mean overall survival
in the cyclin E high expression group was 42 months,
while that in the group without high cyclin E expression
was 38 months. The log-rank test showed a trend towards
better overall survival in the high-cyclin E group but this
was not statistically significance (p = 0.13, Figure 4).
Multivariate survival analysis of clinical covariates in-
cluding age, gender, histologic grade, and stage in EAC,Table 2 High expression of cyclin E in esophageal
adenocarcinoma, low and high dysplasia, Barrett’s






squamous epithelium 84 (97.7) 2 (2.3) 86
Columnar cell
metaplasia
78 (96.3) 3 (3.7) 81
Barrett’s esophagus 32 (94.2) 2 (5.8) 34
Low grade dysplasia 17 (81.0) 4 (19.0) 21
High grade dysplasia 9 (64.3) 5 (35.7) 14
Adenocarcinoma 95 (83.3) 19 (16.7) 114found that age, differentiation and stage (p < 0.05)
have strong association with patient survival, but gender
(p = 0.66) was not significantly associated with patients’
survival in EAC.Correlation of cyclin E high expression and
clinicopathological characteristics
The correlation of high cyclin E expression with clinico-
pathological features was analyzed. High expression of
cyclin E is not associated with age, gender, stage, differ-
entiation and lymph node metastasis (data not shown).Discussion
In this study we found that cyclin E shows a significantly
higher frequency of high expression in neoplastic lesions
(low- and high-grade dysplasia or adenocarcinoma) com-
pared to non-dysplastic tissues (Barrett’s esophagus, col-
umnar cell metaplasia and squamous epithelium). With
SNP DNA microarray study, the amplification of cyclin E
was also present in esophageal adenocarcinoma, but was
not identified in Barrett’s esophagus and columnar cell
metaplasia. In addition, we found that high expression of
cyclin E may be associated with better prognosis although
this did not reach statistical significance.
Sarbia et al. first reported that the expression of cyclin
E in esophagus tissues in small samples was present in 0
of 24 SE (0.0%), 2 of 21 LGD (9.5%), 3 of 17 HGD (17.6%),
and 5 of 35 CA (14.3%) [22]. In our study, cyclin E shows
similar frequency of high expression in 16.7% esophageal
adenocarcinoma (19/114), but a higher frequency of ex-
pression in high grade dysplasia (35.7%) and low grade
dysplasia (19.0%) compared to their study. In addition, we
found that cyclin E is highly expressed with lower rates at
5.8% in Barrett’s esophagus (2/34), 3.7% in columnar cell
metaplasia (3/81), and 2.3% in squamous mucosa (2/86).
Umansky et al. also reported the expression of cyclin E
(43%), p16 (73%), p21 (88%), p27 (95%), and cyclin D1
(47%) in Barrett’s esophagus, which was down-regulated
by acid suppression of proton pump inhibition (PPI).
However, no amplification or deletion was identified by
Southern blot analysis [21]. This suggests that episodes of
acid reflux might trigger proliferation and inhibit pro-
grammed cell death signaling pathways. In our study, no
amplification was identified in Barrett’s esophagus (0/26)
and columnar cell metaplasia (0/25) by SNP DNA micro-
array method. However, high expression of cyclin E (5.8%)
in BE is significant lower than that in Umansky’s study
(43%). The mechanism is unclear how cyclin E is highly
expressed in BE and columnar cell metaplasia without the
amplification. Cyclin E amplification was observed at
13.8% (9/65) [19] and 12.6% (11 of 87) [20] in esophageal






Figure 3 High expression of cyclin E in various histologic types by immunohistochemical studies. Cyclin E immunostain shows weakly
nuclear stain in squamous mucosa (A), columnar cell metaplasia (B) and Barrett’s esophagus (C). Cyclin E shows strong nuclear stain in low grade
dysplasia (D), high grade dysplasia (E) and adenocarcinoma (F).
Zhou et al. BMC Gastroenterology 2014, 14:78 Page 6 of 8
http://www.biomedcentral.com/1471-230X/14/78Cyclin E was reported to be expressed in precancerous
lesion of colon adenocarcinoma [14,24,25]. Expression of
cyclin E has been shown in 25% of colorectal adenomas,
the most important precursor lesions of colorectal carcin-
oma [24]. With 1,2-dimethyl-hydrazine dihydrochlorideTable 3 Comparison of the frequency of cyclin E high
expression between various groups by Fisher exact test
(p value)
















*The frequency of cyclin E high expression shows significantly different
between these pairs.
CCM, Columnar cell metaplasia; BE, Barrett’s Esophagus; LGD, Low grade
dysplasia (LGD); HGD, High grade dysplasia; EAC, Esophageal adenocarcinoma;
SE, Squamous epithelium.(DMH)-induced rat colon adenocarcinoma, cyclin E
expression was detected in 87.5% of the adenomas and
in 92.3% of the adenocarcinomas [25]. Hur and colleagues
also found that cyclin E expression both in the mRNA and
protein levels was present in normal colonic mucosa, ad-
enomas and adenocarcinomas. There was a significant dif-
ference in the degree of expression of cyclin E between
normal mucosa and adenomas, but there was not a signifi-
cant difference between adenomas and adenocarcinomas.
They indicated that cyclin E plays an important role dur-
ing the multistage process of rat colon carcinogenesis, es-
pecially at a relatively early stage [25]. In human samples,
the increase of cyclin E expression also was reported in
colon mucosa. The median of cyclin E expression signifi-
cantly increased in normal through hyperplastic and aden-
omatous tissues and slightly decreased in adenocarcinoma
of colon samples [14], which confirmed the finding in the
rat model and proved that the expression of cyclin E pro-
moted abnormal proliferation of cells during colorectal
carcinogenesis [14]. In the esophagus, our data and previ-
ous studies also showed that the high expression of cyclin
E significantly increased from non-dysplasia group (nor-
mal squamous epithelium, columnar cell metaplasia) to
neoplastic group (low and high grade dysplasia). The high
expression of cyclin E reached its peak in high grade
dysplasia and decreased in adenocarcinoma. Our find-
ings in the esophagus agree to the previous studies in
colon. High expression of cyclin E may play an import-
ant role in early stage of carcinogenesis in esophagus
and could be a potential targeted marker to early inter-
fere with cancer progress and stratify high risk patients
with precancerous lesion for close surveillance.
Figure 4 Kaplan-Meier analysis of overall survival associated with high cyclin E expression in esophageal adenocarcinoma. No significant
association of overall survival with cyclin E high expression (p = 0.13) in 117 EAC patients.
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tic targets in oncology. siRNA treatment significantly re-
duced CCNE1 or cyclin E-CDK-2 complex expression
and significantly inhibited cell growth in CCNE1-ex-
pressing cells, suggesting that CCNE1-targeted therapy
may benefit ovarian, breast and lung cancer patients
with CCNE1 amplification [6,7,10]. In addition, cyclin E
siRNA synergistically enhanced the cell killing effects of
doxorubicin in cell culture and suppressed the tumor
growth in mice. They concluded that cyclin E may serve
as a novel and effective therapeutic target [7]. Our study
showed both amplification and high expression of cyclin
E in esophagus precancerous lesion and adenocarcin-
oma, suggesting the further study of potential effect in
the inhibition of cyclin E expression for target therapy of
esophageal precancerous lesion.
Amplification and high expression of cyclin E were re-
ported to relate with poor prognosis in many different
tumors [8-10,12,14-16,26]. In meta-analysis of lung non-
small cell carcinoma from fourteen studies (2606 cases)
[27], cyclin E over-expression was found to be a strong
predictor of poor prognosis in lung carcinoma patients
(HR: 1.38, 95% CI: 1.07-1.79; P = 0.014). In ovarian cancer,
the amplification was identified in 18 (20%) of 88 ovarian
carcinoma, which was significantly correlated with shorter
disease-free survival and overall survival [10]. In gastric
[11] and colorectal adenocarcinoma [28], overexpression
of cyclin E was a potential prognostic markers. It is sur-
prising to find both amplification and high expression
of cyclin E in esophageal adenocarcinoma in our study
were not significantly associated with patient overall
survival, even with a little better overall survival rate
with high expression of cyclin E. The controversial data
for the prognosis was reported in the colon [29,30],
ovary [31], stomach [11,12] and lung [9]. In the esopha-
gus, similar to the cyclin E study, we recently found that
HER2 amplification and expression were associated
with better but not significantly better prognoses [32],
which is confirmed by a Mayo clinical study [33]. They
further proved that HER2 positivity was significantlyassociated with a better survival. Therefore, the function
of oncogene may play different roles in various organs
or tumors. Furthermore, our findings needs to be con-
firmed by different studies since the cyclin E expression
and amplification are associated with the sensitivity of
methods, race of patients, location of tumors and pre-
operative neoadjuvant therapy.
Conclusions
The high expression of cyclin E significantly increases
from non-dysplasia esophageal lesion, to low and high
grade dysplasia. It implies that cyclin E may play an im-
portant role in early stage of carcinogenesis and could be a
potential marker for a target therapy of precancerous le-
sion. In addition, the amplification and high expression
of cyclin E are associated with a better prognosis, but
not statistically significant.
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